Treatment-related Death in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis

Clinical Oncology

Volumn 29, Issue 4, 2017, Pages 218-230

  Abdel Rahman, O ^a,b   Helbling, D ^b   Schmidt, J ^c   Petrausch, U ^d   Giryes, A ^b   Mehrabi, A ^e   Schob O ^c   Mannhart, M ^f   Oweira, H ^c,e  

^a AIN SHAMS UNIVERSITY   (Egypt)

^b Gastrointestinal Tumor Center Zurich   (Switzerland)

^c Hirslanden Hospital   (Switzerland)

^d Swiss Tumor Immunology Institute   (Switzerland)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f Center of Zug   (Switzerland)

Author keywords

Atezolizumab; ipilimumab; nivolumab; pembrolizumab; treatment related death; tremelimumab

Indexed keywords

ANTINEOPLASTIC AGENT; ATEZOLIZUMAB; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; TICILIMUMAB; CTLA4 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; DEATH; HUMAN; MALIGNANT NEOPLASM; MEDLINE; META ANALYSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SYSTEMATIC REVIEW; ADVERSE DRUG REACTION; ANTAGONISTS AND INHIBITORS; MORTALITY; NEOPLASMS; RISK ASSESSMENT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CTLA-4 ANTIGEN; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; NEOPLASMS; RISK ASSESSMENT;

EID: 85007330328     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2016.11.007     Document Type: Article

References (35)

1. [1] Momtaz, P., Postow, M.A., Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway. Pharmgenomics Pers Med, 7, 2014, 357.
2. [2] Rosenberg, S.A., Yang, J.C., Restifo, N.P., Cancer immunotherapy: moving beyond current vaccines. Nat Med 10:9 (2004), 909–915.
3. [3] Hodi, F.S., O'Day, S.J., McDermott, D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:8 (2010), 711–723.
4. [4] Robert, C., Thomas, L., Bondarenko, I., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:26 (2011), 2517–2526.
5. [5] Hamid, O., Robert, C., Daud, A., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369:2 (2013), 134–144.
6. [6] Robert, C., Schachter, J., Long, G.V., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:26 (2015 Jun 25), 2521–2532.
7. [7] Garon, E.B., Rizvi, N.A., Hui, R., et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:21 (2015 May 21), 2018–2028.
8. [8] Fehrenbacher, L., Spira, A., Ballinger, M., et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387:10030 (2016 Apr 30), 1837–1846.
9. [9] Brahmer, J.R., Tykodi, S.S., Chow, L.Q., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:26 (2012), 2455–2465.
10. [10] Abdel-Rahman, O., ElHalawani, H., Fouad, M., Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis. Future Oncol 11:17 (2015), 2471–2484.
11. [11] Abdel-Rahman, O., ElHalawani, H., Fouad, M., Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Expert Opin Drug Saf 14:10 (2015 Oct), 1507–1518.
12. [12] Abdel-Rahman, O., ElHalawani, H., Fouad, M., Risk of endocrine complications in cancer patients treated with immune check point inhibitors; a meta-analysis. Future Oncol 12:3 (2016 Feb), 413–425.
13. [13] Abdel-Rahman, O., ElHalawani, H., Fouad, M., Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors; a meta-analysis. Immunotherapy 7:11 (2015), 1213–1227.
14. [14] Westin, J.R., Chu, F., Zhang, M., et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 15:1 (2014), 69–77.
15. [15] Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151:4 (2009), 264–269.
16. [16] DerSimonian, R., Laird, N., Meta-analysis in clinical trials. Control Clin Trials 7:3 (1986), 177–188.
17. [17] Kwon, E.D., Drake, C.G., Scher, H.I., et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 15:7 (2014), 700–712.
18. [18] Brahmer, J., Reckamp, K.L., Baas, P., et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:2 (2015 Jul 9), 123–135.
19. [19] Robert, C., Long, G.V., Brady, B., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:4 (2015), 320–330.
20. [20] Weber, J.S., D'Angelo, S.P., Minor, D., et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16:4 (2015), 375–384.
21. [21] Borghaei, H., Paz-Ares, L., Horn, L., et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:17 (2015 Oct 22), 1627–1639.
22. [22] Reck, M., Bondarenko, I., Luft, A., et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol 24:1 (2013), 75–83.
23. [23] Eggermont, A.M., Chiarion-Sileni, V., Grob, J.-J., et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 16:5 (2015), 522–530.
24. [24] Ribas, A., Kefford, R., Marshall, M.A., et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 31:5 (2013), 616–622.
25. [25] Lynch, T.J., Bondarenko, I., Luft, A., et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non–small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 30:17 (2012), 2046–2054.
26. [26] Motzer, R.J., Escudier, B., McDermott, D.F., et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:19 (2015 Nov 5), 1803–1813.
27. [27] Ribas, A., Puzanov, I., Dummer, R., et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16:8 (2015 Aug), 908–918.
28. [28] Herbst, R.S., Baas, P., Kim, D.-W., et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:10027 (2016 Apr 9), 1540–1550.
29. [29] Postow, M.A., Chesney, J., Pavlick, A.C., et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372:21 (2015), 2006–2017.
30. [30] Larkin, J., Chiarion-Sileni, V., Gonzalez, R., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:1 (2015 Jul 2), 23–34.
31. [31] Abdel-Rahman, O., Immune checkpoints aberrations and gastric cancer; assessment of prognostic value and evaluation of therapeutic potentials. Crit Rev Oncol Hematol 97 (2016 Jan), 65–71.
32. [32] Johnson, D.B., Friedman, D.L., Berry, E., et al. Survivorship in immune therapy: assessing chronic immune toxicities, health outcomes, and functional status among long-term ipilimumab survivors at a single referral center. Cancer Immunol Res 3:5 (2015), 464–469.
33. [33] Johnston, R., Lutzky, J., Chodhry, A., Barkin, J., Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab. Dig Dis Sci 54:11 (2009), 2538–2540.
34. [34] Min, L., Hodi, F.S., Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis. Cancer Immunol Res 2:1 (2014), 15–18.
35. [35] Faje, A.T., Sullivan, R., Lawrence, D., et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab 99:11 (2014), 4078–4085.